🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

195 results for “Boehringer Ingelheim” Clear

  1. Empagliflozin

    Boehringer Ingelheim

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  2. Iclepertin

    Boehringer Ingelheim

    Schizophrenia

    phase 3 small molecule terminated

    2 trials

  3. Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517

    Boehringer Ingelheim

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  4. Jardiance 10 mg film-coated tablets, empagliflozin, Placebo matching empagliflozin, film-coated tablets

    Boehringer Ingelheim

    Chronic kidney disease in paediatric patients

    phase 3 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer Ingelheim

    non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  6. Linagliptin

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials

  7. Metalyse 5 000 units (25 mg) powder for solution for injection

    Boehringer Ingelheim

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  8. Nintedanib

    Boehringer Ingelheim

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule completed

    1 trial

  9. Nintedanib

    Boehringer Ingelheim

    Lung Diseases, Interstitial

    phase 3 small molecule completed

    1 trial

  10. OPDIVO 10 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, Tecentriq 1 200 mg concentrate for solution for infusion

    Boehringer Ingelheim

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  11. Olodaterol (BI 1744)

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    2 trials

  12. Pemetrexed

    Boehringer Ingelheim

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  13. Placebo

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials

  14. Placebo matching BI 1015550, BI 1015550, BI 1015550

    Boehringer Ingelheim

    Interstitial lung diseases, Familial pulmonary fibrosis, Pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  15. Placebo matching BI 1291583, BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial

  16. Placebo matching to spesolimab

    Boehringer Ingelheim

    Pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  17. Pramipexol Extended Release

    Boehringer Ingelheim

    Early Parkinson Disease (Early PD)

    phase 3 small molecule completed

    1 trial

  18. Spesolimab - solution for infusion

    Boehringer Ingelheim

    Netherton Syndrome

    phase 3 small molecule terminated

    1 trial

  19. Spesolimab i.v.

    Boehringer Ingelheim

    Hidradenitis Suppurativa

    phase 3 small molecule completed

    1 trial

  20. Spesolimab, Placebo matching to Spesolimab

    Boehringer Ingelheim

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  21. Tecentriq 1 200 mg concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BI 764532, RoActemra 20 mg/mL concentrate for solution for infusion

    Boehringer Ingelheim

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  22. Warfarin

    Boehringer Ingelheim

    Thromboembolism

    phase 3 small molecule completed

    1 trial

  23. dabigatran dose 1

    Boehringer Ingelheim

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  24. dabigatran etexilate

    Boehringer Ingelheim

    Venous Thromboembolism

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources